Eptinezumab - Lundbeck Seattle BioPharmaceuticals
Alternative Names: ALD-403; Eptinezumab-jjmr; Lu-AG09221; VYEPTILatest Information Update: 25 Jun 2025
At a glance
- Originator Alder Biopharmaceuticals
- Developer Lundbeck A/S; Lundbeck Seattle BioPharmaceuticals Inc.
- Class Analgesics; Antimigraines; Monoclonal antibodies
- Mechanism of Action Calcitonin gene-related peptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- Phase III Cluster headache
Most Recent Events
- 21 Jun 2025 Efficacy and adverse event data from the phase III SUNRISE trial in Migrane released by Lundbeck A/S
- 04 Apr 2025 Efficcay data from the phase III PREVAIL trial in Migraine released by Lundbeck A/S
- 17 Feb 2025 Lundbeck A/S completes the Phase-III Sunrise trial in Migraine (Prevention) in South Korea, China, Georgia, Japan, Poland, Slovakia, Spain, Taiwan (IV, Infusion) (NCT04921384)